Highlights

  • Third quarter 2026 net loss was $297.1 million, compared with $212.8 million, and net loss per share was $1.99.
  • Research and development expenses were $270.3 million in the third quarter, compared with $209.9 million a year earlier.
  • In October 2026, Vaxcyte completed public offerings with gross proceeds of approximately $1.15 billion, including $575 million of convertible notes.
  • Cash, cash equivalents and investments were $2.3 billion at September 30, 2026, and the accumulated Deficit was $3.1 billion.

Vaxcyte, Inc. (NASDAQ:PCVX) shares were trading at USD 56.35 on November 20, 2026, down 3.44%, with a relative Volume at time of 1.89. The clinical-stage Vaccine company announced OPUS-1 trial results for VAX-31 in October 2026, completed concurrent public offerings that month and filed its report for the quarter ended September 30, 2026 on November 4.

Vaxcyte is a Delaware corporation with principal executive offices in San Carlos, California. It is a vaccine innovation company engineering vaccines to protect against bacterial diseases through its XpressCF cell-free protein synthesis platform. Its pneumococcal conjugate vaccine candidates are VAX-31, VAX-24 and VAX-XL, which are broad-spectrum and carrier-sparing. The company has not generated Revenue from commercial product sales, relies on third-party Manufacturing partners and reports on a calendar year ending December 31.

Third Quarter 2026 Results

For the three months ended September 30, 2026, Research and Development expenses were $270.3 million, compared with $209.9 million a year earlier. General and administrative expenses were $37.9 million, compared with $32.4 million. Total operating expenses were $308.3 million, compared with $242.4 million, and the loss from operations was $308.3 million, compared with $242.4 million.

Interest income was $23.2 million, compared with $29.3 million, and other expense was $12.0 million, compared with other income of $0.29 million. Net loss was $297.1 million, compared with $212.8 million, and net loss per share, basic and diluted, was $1.99, compared with $1.56.

Nine-Month Results

For the nine months ended September 30, 2026, research and development expenses were $851.0 million, compared with $552.2 million, and general and administrative expenses were $105.9 million, compared with $97.1 million. Net loss was $902.0 million, compared with $520.1 million, and net loss per share was $6.25, compared with $3.83. Net cash used in Operating Activities was $737.2 million, compared with $430.7 million.

Balance Sheet and Liquidity

At September 30, 2026, cash and cash equivalents were $125.5 million, compared with $174.0 million at December 31, 2025. Short-term investments were $1.17 billion, compared with $1.39 billion, and Long-Term Investments were $972.2 million, compared with $881.7 million. Total Assets were $2.99 billion, compared with $3.00 billion. Total stockholders' Equity was $2.49 billion, compared with $2.69 billion.

The company reported cash, cash equivalents and investments of $2.3 billion and an accumulated deficit of $3.1 billion. It said it believes its cash, cash equivalents and investments will be sufficient to fund its operating expenses and Capital Expenditure requirements through at least 12 months from the filing date, and that it expects its expenses to remain high.

October 2026 Public Offerings

In October 2026, Vaxcyte completed concurrent underwritten public offerings of 8,584,375 shares of common stock at $64.00 per share, pre-funded warrants to purchase 400,000 shares at $63.999 per warrant, and $575 million aggregate principal amount of 1.50% convertible senior notes due 2032. The offerings included full exercise of the underwriters' Options to purchase up to 1,171,875 additional shares and up to an additional $75 million of notes. Aggregate net proceeds were approximately $1.1 billion, and the company is assessing the accounting effects of the offerings.

VAX-31 OPUS-1 Results and Pipeline

In October 2026, Vaxcyte announced topline results from OPUS-1, a randomized, double-blind, active-controlled Phase 3 trial of VAX-31 in pneumococcal-naive U.S. adults aged 50 years and older (n=3,572), with a separate cohort aged 18-49 years (n=475). The company said VAX-31 met all prespecified primary endpoints across age groups compared to PCV20 and PCV21.

The company expects to report OPUS-2 and OPUS-3 safety, tolerability and immunogenicity data in the first half of 2027. It is planning a manufacturing consistency study as the final Phase 3 study to enable the submission of a Biologics License Application. The FDA has granted Breakthrough Therapy Designation for VAX-31 in adults.